Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neoplasm Metastasis 2Sarcoma 1Rhabdomyosarcoma 1Neoplasms 1Medulloblastoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Melphalan 4Irinotecan 4Filgrastim 4Cyclophosphamide 4Busulfan 4fludarabine 3Topotecan 3Temozolomide 3Granulocyte Colony-Stimulating Factor 3pegfilgrastim 2liposomal doxorubicin 2Thiotepa 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Doxorubicin 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1ribociclib 1regorafenib 1poly ICLC 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1omburtamab I-131 1olaparib 1mocetinostat 1lexatumumab 1irinotecan sucrosofate 1fludarabine phosphate 1cixutumumab 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Rhabdomyosarcoma × LY2940680 × Clear all
NCT01697514 2013-08-27

A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma

Eli Lilly and Company

Phase 1 Withdrawn
CNSSarcoma

Medulloblastoma, Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡